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ARTICLE
 
Immunocytochemical Phenotyping of Disseminated Tumor Cells 
in Bone Marrow by uPA Receptor and CK18: Investigation of 
Sensitivity and Specificity of an Immunogold/Alkaline 
Phosphatase Double Staining Protocol
 
Heike Allgayer, Markus Maria Heiss, Rainer Riesenberg, Rudolf Babic, Karl Walter Jauch, 
and Friedrich Wilhelm Schildberg 
 
Departments of Surgery (HA,MMH,KWJ,FWS), and Urology (RR), Klinikum Grosshadern, Ludwig-Maximilians University of 
Munich, Munich, Germany, and Institute of Pathology and Cytology (RB), Deggendorf, Germany
 
SUMMARY
 
Phenotyping of cytokeratin (CK)18-positive cells in bone marrow is gaining in-
creasing importance for future prognostic screening of carcinoma patients. Urokinase-type
plasminogen activator receptor (uPA-R) is one example of a potential aggressive marker for
those cells. However, a valid and reliable double staining method is needed. Using mono-
clonal antibodies against uPA-R and CK18, we modified an immunogold/alkaline phos-
phatase double staining protocol. UPA-R/CK18-positive tumor cell controls exhibited black
uPA-R staining in 15–80% of cases and red CK18 staining in almost 100% of tumor cells. Iso-
type- and cross-matched controls were completely negative. Bone marrow from healthy
donors was always CK18-negative. Reproducibility of CK18-positive cell detection was esti-
mated in a series of specimens from 61 gastric cancer patients comparatively stained with
the single alkaline phosphatase–anti-alkaline phosphatase (APAAP) and our double stain-
ing method (10
 
6
 
 bone marrow cells/patient). In four cases, double staining could not repro-
duce CK18-positive cells. In 34 cases it revealed fewer or equal numbers, and in 23 cases
more CK18-positive cells than the APAAP method. Overall quantitative analysis of detected
cell numbers (838 in APAAP, range 1–280 in 10
 
6
 
; double staining 808, range 0–253) demon-
strated relative reproducibility of APAAP results by double staining of 97%. Correlation of
results between both methods was significant (
 
p
 
,
 
0.001, linear regression). Sensitivity of
double staining tested in logarithmic tumor cell dilutions was one CK18-positive cell in
300,000. Specific uPA-R staining was seen on CK18-positive cells in bone marrow from 29 of
61 patients, and also on single surrounding bone marrow cells. To test the specificity of this
staining, bone marrow cytospins from 10 patients without tumor disease were stained for
uPA-R with the APAAP method. uPA-R expression was confirmed in all 10 cases, with a
mean of 6.5% uPA-R-positive cells in 1000 bone marrow cells (SEM 1.2%). These results sug-
gest that our double staining protocol is a sensitive, reproducible, and specific method for
routine uPA-R phenotyping of disseminated CK18-positive cells in bone marrow of carci-
noma patients.
 
(J Histochem Cytochem 45:203–212, 1997)
 
M
 
inimal
 
 residual tumor disease in solid epithelial
cancers has been indicated during the last years by in-
vestigations of disseminated tumor cells in bone mar-
row identified by the marker cytokeratin 18 (CK18), a
cytoskeletal component of simple epithelial and carci-
noma-derived cells (Moll et al. 1982). The sensitivity
and specificity of this marker against the mesenchymal
background of bone marrow cells have been repeat-
edly demonstrated (Pantel et al. 1994; Pantel et al.
1993b; Riesenberg et al. 1993; Lindemann et al. 1992;
Schlimok et al. 1987). Correlation with clinical prog-
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nosis (Jauch et al. 1996; Pantel et al. 1993a; Linde-
mann et al. 1992; Moss et al. 1991; Berger et al. 1988)
and demonstration of dynamic postoperative develop-
ment after curative tumor resection of CK18-positive
cells in bone marrow being associated with later clini-
cal outcome (Heiss et al. 1995a) suggest the biological
relevance of these cells with clinical implications.
Our earlier results regarding the correlation of
urokinase-type plasminogen activator receptor (uPA-R)
on those cells, with their postoperative quantitative in-
crease (Heiss et al. 1995a), also point to the clinical
importance of their phenotypic characterization. uPA-R
as a central representative of the urokinase system, a
pattern of factors known to be involved in tumor-asso-
ciated proteolysis and potentially to represent a tumor
cell’s invasive capacity (Blasi 1993; Moller 1993), may
indicate aggressive phenotypes of disseminated tumor
cells. Other parameters also, such as the tyrosin kinase
receptor Erb-B2 (Pantel et al. 1993b) which is poten-
tially associated with aggressive tumor cell growth,
proliferation antigens (Pantel et al. 1993b), or tissue-
specific antigens such as prostate-specific antigen (PSA)
(Riesenberg et al. 1993), have already been identified
on CK18-positive cells in bone marrow and may help
in estimating their biological properties and tumor cell
identity.
For reliable phenotyping of disseminated tumor cells,
an immunocytochemical double staining method that
can detect CK18-positive cells against the mesenchy-
mal background of bone marrow with high sensitivity
and reproducibility is necessary. The second antigen
should be unequivocally identified as to its cellular lo-
calization, in good contrast to CK18 staining and with-
out any crossreactivity. 
Riesenberg et al. (1993) introduced a combination
of immunogold staining with the immunocytochemi-
cal alkaline phosphatase (AP) technique for detection
of PSA on disseminated CK18-positive cells in bone
marrow of prostate cancer patients. We modified this
double staining method for identification of uPA-R on
disseminated tumor cells and, as stated, the first clini-
cal results with this new protocol have recently been
presented (Heiss et al. 1995a). The aim of the present
study was to demonstrate the methodological power
of our method. Therefore, we applied our modified
double staining protocol for identification of uPA-R
and CK18 to a series of 61 gastric cancer patients who
had ostensibly exhibited a positive CK18 bone mar-
row status at surgery, as analyzed with the interna-
tionally accepted APAAP (alkaline phosphatase–anti-
alkaline phosphatase) method (Cordell et al. 1984).
We also applied it to logarithmic tumor cell dilutions
and to bone marrow of individuals without malig-
nancy. In the following, we demonstrate our results
concerning the methodological aspects of our double
staining technique, introducing this method as a sensi-
tive and reproducible application for routine pheno-
typing of disseminated tumor cells in carcinoma pa-
tients. 
 
Materials and Methods
 
Patients
 
Bone marrow was taken from 219 patients who underwent
surgery for gastric cancer. As a first step, APAAP staining
was performed to screen those patients for CK18-positive
cells in bone marrow. A total of 61 patients with positive
CK18 results in APAAP and at least 10
 
6
 
 bone marrow cells
left for a second screening with our double staining method
were involved in the present study. 
 
Bone Marrow Aspirates
 
Bone marrow was taken intraoperatively from both iliac
crests (5 ml each) and heparinized. Immediately after aspira-
tion, the bone marrow underwent Ficoll–Hypaque density
centrifugation (Loos and Roos 1974) (density 1.077; Bio-
chrom, Berlin, Germany) for isolation of mononuclear cells
(2000 g/25 min). The interphase fraction was washed twice
in PBS, resuspended to a final concentration of 10
 
6
 
 cells/ml,
and cytocentrifuged on glass slides (10
 
5
 
 cells/slide). After air-
drying for 12–24 hr, the preparations were stained immedi-
ately or stored at 
 
2
 
80C.
 
Immunocytochemical APAAP Staining
 
APAAP staining for CK18-positive cells (Cordell et al. 1984)
was done as a prerequisite to a later investigation with the
double staining procedure. A total of 10
 
6
 
 cells/patient were
analyzed. After fixation (acetone, 7 min) and incubation
with 20% AB serum/PBS for 25 min to reduce unspecific
staining, cells were incubated with MAb CK2 against cyto-
keratin component 18 (Boehringer, Mannheim, Germany;
4 
 
m
 
g/ml, IgG
 
1
 
, 45 min), rabbit anti-mouse bridging antibody
(Dako, Hamburg, Germany; 3 mg/ml, 1:25, 30 min), and
monoclonal mouse APAAP complex (Dako; 0.17 mg/ml,
1:100, 30 min) in a moist chamber. Specifically bound AP
was visualized with a solution containing 0.2 mg/ml naph-
thol AS-MX phosphate (dissolved in dimethyl-formamide;
Sigma, Deissenhofen, Germany), 1% Fast Blue BB salt 1 mg/ml
(Sigma), 0.1 M Tris buffer (pH 8.2), and 0.25 mg/ml levami-
sole (Sigma) to block endogeneous phosphatase activity.
Each assay was controlled negatively by one slide stained
with nonspecific IgG
 
1
 
 (MOPC 21; Sigma) instead of CK2
and a slide of bone marrow from a healthy donor stained for
CK18, and positively by a slide of the CK18-positive colon
cancer cell line HT-29 resp. gastric cancer cell line KATO-III.
 
Immunocytochemical Double Staining
 
Biotinylation of MAb CK2 was done by dissolving 1 mg/ml
CK2 in 25 
 
m
 
g 
 
d
 
-biotinyl-
 
e
 
-aminocaproyl-
 
N
 
-hydroxysuccin-
imide (Boehringer) and 50 
 
m
 
l dimethyl-formamide (DMF),
overnight incubation, and membrane ultrafiltration with a
Centricon centrifugal microconcentrator (Amicon; Witten,
Germany) to separate DMF and uncoupled biotin (Bonnard
et al. 1984; Blatt and Robinson, 1968).
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A modified double staining protocol based on the method
described by Riesenberg et al. (1993) was applied in a moist
chamber. Slides were fixed in acetone for 7 min and incu-
bated in 20% AB serum/PBS for 25 min. All antibodies were
diluted in 10% AB-serum/PBS, and each incubation step was
followed by thoroughly washing the slides three times in
PBS. A mouse MAb against uPA-R specifically recognizing
membrane-bound and intracellular uPA-R (#3936, 10 
 
m
 
g/ml,
IgG
 
2
 
a
 
; American Diagnostica, Greenwich, CT) was incubated
for 60 min, followed by gold-labeled goat anti-mouse anti-
body for 30 min (0.08 mg/ml, 1:50, Auroprobe One Reagent;
Amersham, Braunschweig, Germany). To avoid crossreac-
tions, 10% mouse serum/PBS (Dako) was applied for 25 min.
The second part of the double staining was performed us-
ing biotinylated CK2 MAb (10 
 
m
 
g/ml, 45 min) and AP-con-
jugated streptavidin (1.1 mg/ml, 1:100, 30 min; Jackson Im-
munoResearch, West Grove, PA). In contrast to Riesenberg
et al.(1993), this was not followed by postfixation in glut-
araldehyde.
Visualization of specifically bound CK2 was done with
new fuchsin dye (0.40 mg/ml; Serva, Heidelberg, Germany),
sodium nitrite (0.04 mg/ml; Merck, Darmstadt, Germany),
levamisole (0.36 mg/ml; Sigma), 0.2 M Tris buffer (pH 8.7),
and naphthol AS-BI phosphate (0.08 mg/ml; Sigma) dis-
solved in DMF.
After washing the slides thoroughly in bidistilled water,
specifically bound 1-nm colloidal gold particles (uPA-R
staining) were visualized by silver enhancement under micro-
scopic control. Equal volumes of inducer and enhancer of a
silver enhancement kit (Amersham) were mixed and immedi-
ately incubated at room temperature for a maximum of 40
min. The silver kit was completely exchanged after 20-min
incubation to avoid unspecific precipitation of silver gran-
ules. Slides were washed in bidistilled water and mounted
with Kaiser’s glycerol gelatin (Merck).
For comparison of sensitivity between this method and
the original protocol of Riesenberg et al.(1993), prepara-
tions of the tumor cell dilutions (see below) were addition-
ally stained using 8 
 
m
 
g biotinylated CK2 instead of 10 
 
m
 
g
5% mouse serum/PBS for 20 min and 2% glutaraldehyde/
PBS (10 min) for postfixation after the incubation of strepta-
vidin. 
Slides of colon cancer cell lines SW403 and HT29
(ATCC; Rockville, MD) treated under the same conditions
served as positive controls. For isotype crossreactivity con-
trols, MAb CK2 was replaced by murine IgG
 
1
 
 (MOPC21;
Sigma) and MAb against uPA-R by murine IgG
 
2
 
a
 
 (UPC 10;
Sigma) in equimolar protein concentrations. Two other slides
were stained without the first bridge and the second primary
antibody, and vice versa. Two further slides underwent the
staining procedure without the first second bridge. Bone
marrow of a healthy donor served as another control. 
 
Tumor Cell Dilutions for Determination of Sensitivity
 
The sensitivity of our method regarding detection of CK18-
positive cells required testing in comparison to the original
protocol (Riesenberg et al. 1993). Therefore, SW403 tumor
cells were logarithmically diluted in peripheral blood leuko-
cytes (PBL) to 1 tumor cell in 10
 
6
 
, with additional dilutions
of 1:200,000, 1:300,000, and 1:500,000. Solutions were cy-
tocentrifuged (10
 
5
 
 cells/slide) as described previously. Dilu-
tions were analyzed for number of tumor cells detected and
intensity of tumor cell staining. The results of this investiga-
tion were confirmed twice by two further replicates of the
dilution. 
 
Modification of the Double Staining Protocol
 
The original protocol of Riesenberg et al. (1993) was ini-
tially tested on 10 slides with 10
 
5
 
 cells each of each tumor
cell dilution described above. This revealed that the sensitivity
for detecting CK18-positive cells was not optimal (1:10,000).
Therefore, 11 further experiments were performed to im-
prove the sensitivity, each confirmed by one further replicate
of the tumor cell dilution: CK2 antibody was tested in two
higher concentrations (10 and 12 
 
m
 
g/ml), streptavidin was
increased to 1:80 and 1:50 in two other experiments, and
glutaraldehyde postfixation was omitted in another series.
Background staining was seen with the higher CK2 and
streptavidin concentrations. Therefore, in four further tests
mouse serum was increased to 10% compared to 5%, in
combination with higher antibody and streptavidin concen-
trations. Background staining was not present at 10 
 
m
 
g/ml
CK2 antibody, and the staining intensity of cells was im-
proved. However, the sensitivity in dilutions was not signifi-
cantly increased. Background was still seen with higher
streptavidin and 12 mg/ml CK2. Therefore, we settled on a
protocol with 10 
 
m
 
g/ml CK2 and streptavidin 1:100.
The sensitivity increased to 1:100,000 with the omission
of glutaraldehyde postfixation. This was not diminished in a
second experiment with 10% mouse serum and omission of
postfixation.
A final protocol was therefore established with 10 
 
m
 
g/ml
CK2, 10% mouse serum, and omission of glutaraldehyde.
Testing at logarithmic tumor cell dilutions comparing the
modified protocol with the original was now done according
to the preceding paragraph. 
 
Investigation of uPA-R Expression in Normal Bone 
Marrow Cytospins
 
Expression of uPA-R in cultured normal bone marrow stim-
ulated with cytokines has been recently described (Plesner et
al. 1994). To ensure the specificity of our double staining
protocol, which detected uPA-R in normal control bone mar-
row (see Results), we investigated expression of uPA-R in bone
marrow from 10 control patients (10
 
6
 
 cells each) from our
surgical department using the single APAAP protocol de-
scribed above and MAb against uPA-R (American Diagnos-
tica). The patients enrolled underwent surgery for nonmalig-
nant diseases: one for abdominal aortic aneurysm, two for
arterial occlusion, two for inguinal hernia, one for leiomyoma,
and one for rectal adenoma. One patient underwent bone
marrow biopsy because of hemolytic anemia, and one healthy
member of our clinic gave informed consent for bone mar-
row donation. A total of 1000 bone marrow cells per patient
were counted representatively for detection of uPA-R.
 
Analysis of Staining Results
 
All slides (including tumor cell dilutions) were coded and in-
dependently analyzed by two blinded investigators. Bone
marrow preparations from patients were screened without
knowledge of patient identity or stage of disease. Cell num-
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Figure 1 Example of a CK18-positive cell in bone marrow at 1:400 magnification, illustrating easy detectability of positive cells with our
method even at low power. Bar 5 50 mm.
Figure 2 Two cells expressing uPA-R (black, arrowheads) and CK18 (red). Original magnification 3 1000. Bar 5 20 mm.
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expressing uPA-R (Plesner et al. 1994; Wilson et al.
1983) could lead to false-positive results. uPA-R was
detected in bone marrow of all the patients included in
this study. Table 1 shows the clinical diagnosis, num-
ber of uPA-R-positive bone marrow cells in 1000, and
the corresponding percentages. The mean percentage
of uPA-R-expressing bone marrow cells was 6.5%
(
 
6
 
1.2%).
 
Sensitivity of the Double Staining Protocol
 
The sensitivity of detection of expected CK18-positive
cells was tested with tumor cell dilutions (SW403/
PBL) described above (see Materials and Methods) us-
ing the original staining protocol of Riesenberg et al.
(1993). Tumor cells in expected quantities and easily
visible staining could be detected only up to a dilution
of 1:10,000 and at very reduced staining intensity in
the dilution of 1:100,000 (Table 2). Therefore, we
modified this protocol step by step, testing each modi-
fication with the tumor cell dilutions described (see
Materials and Methods).
With a double staining protocol using 10 
 
m
 
g/ml bi-
otinylated MAb CK2 and omitting the postfixation
step with glutaraldehyde, we could optimize sensitiv-
ity up to 1 tumor cell in 300,000, with good visibility
of stained cells. The results of this modified protocol
compared to the original are shown in Table 2, which
gives means and standard deviations of cell counts
found in 10 slides with 10
 
5
 
 bone marrow cells each.
The results were confirmed by two replicates of the tu-
mor cell dilution, one revealing no positive cells at di-
lutions of 1:100,000 and higher with the original pro-
tocol and 4 cells in 10 slides at 1:300,000 with the
modified method, the second showing three hardly
visible positive cells in 10
 
6
 
 at 1:100,000 with the orig-
inal (higher dilutions negative) and two clearly detect-
able cells at 1:300,000 with the modified protocol,
with expected tumor cell numbers in all lower dilutions.
 
Estimation of Reproducibility of CK18-positive 
Cell Detection
 
Of our 61 patients, 1 million bone marrow cells (10
slides with 10
 
5
 
 cells each) were stained with our modi-
fied double staining protocol and with the APAAP–
Fast Blue method as well, as positive CK18 counts in
the single APAAP method were defined as prerequisite
for additional double staining. Therefore, comparison
between quantitative CK18-positive results of both
methods was expected to allow an estimation of the
reproducibility of our double staining technique.
 
bers detected by double staining were counted independently
from single APAAP results.
 
Statistical Analysis
 
A correlation diagram (scatter plot) with calculation of the
regression line and linear regression analysis (level of signifi-
cance 
 
p
 
,
 
0.05) was applied for estimation of correlation be-
tween CK18-positive cell numbers detected in APAAP–Fast
Blue and the double staining method, using the EDA statisti-
cal software package (Department of Medical Information,
Biometry and Epidemiology, Klinikum Grosshadern, Mu-
nich, Germany). This program was also used for calculation
of means, standard deviations (SD), and standard errors of
the mean (SEM).
 
Results
 
Staining Results and Controls
 
CK18-positive cells were easily detected by deep brown-
ish-red staining of the cell cytoplasm, even at low mag-
nifications (Figures 1 and 3). Bone marrow from healthy
donors was routinely stained as a negative control in
each assay, and never exhibited CK18-positive cells.
Expression of uPA-R on CK18-positive cells was
indicated by black-grained linear staining of cell mem-
branes (Figure 2). In some cases the staining appeared
adjacent to nuclear membranes (Figure 4). Between 10
and 50 of 1000 surrounding bone marrow cells re-
vealed specific staining for uPA-R. The specificity of
this phenomenon was investigated in bone marrow
from 10 donors with nonmalignant diagnoses (see be-
low). UPA-R expression by CK18-positive cells was
detected in 29 of the 61 patients investigated. 
The tumor cell lines SW403 and HT29 showed al-
most 100% CK18-expression, with uPA-R expression
between 15–80%, depending on the culture passage.
A maximal percentage of uPA-R expression could be
found at the beginning of tumor cell culture.
All isotype controls were negative, and neither spe-
cific nor unspecific red or black staining was detected. 
 
UPA-R Expression in Normal Bone Marrow
 
To prove the specificity of uPA-R staining of bone
marrow cells in our double staining method, we also
stained bone marrow cytospin preparations from 10
patients with nonmalignant disease for uPA-R, using
the established APAAP–Fast Blue protocol (Cordell et
al. 1984). Patients with leukemia or lymphoma were
excluded from this investigation because potential bone
marrow infiltration with atypical leukocytes probably
 
Figure 3 
 
CK-18-positive cell in bone marrow without uPA-R staining. Original magnification 
 
3
 
 1000. Bar 
 
5
 
 20 
 
m
 
m.
 
Figure 4
 
UPA-R detection (black) adjacent to the nuclear membrane (arrow) of a CK18-positive cell. Original magnification 
 
3
 
 1000. Bar 
 
5
 
20 
 
m
 
m.
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Detailed quantitative results of both methods are
given in Figure 5 for each of the patients. It shows
comparison of cells detected in APAAP (y-axis) with
double staining (x-axis).
In four cases (7%), our double staining method was
unable to detect CK18-positive cells again. Therefore,
the reproducibility of qualitative cell detection in
APAAP by double staining was estimated as 93%. 
In 56% of cases (
 
n
 
5
 
34), double staining found
fewer or equal cell numbers. In the four patients with
zero redetection of cells by double staining, 7 cells had
been found altogether with the APAAP technique (for
the single cases range 1–3 cells in 10
 
6
 
, mean 2.0, SD
0.8). In six further patients, APAAP detected 17 cells
altogether (range 1–4 in 10
 
6
 
 in the individual case,
mean 2.8, SD 1.2), and the double staining method
could redetect the same cell numbers again. In 24 pa-
tients, APAAP staining revealed 653 cells in total
(range 2–280 in 10
 
6
 
 per individual, mean 27.2, SD
54.2), and with 495 cells altogether double staining
redetected fewer CK18-positive cells (range 1–253 in
10
 
6
 
, mean 21.5, SD 48.9). In 44% of cases (
 
n
 
5
 
27)
double staining found more CK18-positive cells in
bone marrow than did the APAAP–Fast Blue method.
APAAP had revealed a total of 161 cells in these 27
patients (for each case range 1–40 in 10
 
6
 
, mean 6.0,
SD 8.0), and the double staining method found 296
cells (range 1–53 in 10
 
6
 
, mean 11.0, SD 10.9). Over-
all, a relative quantitative CK18-positive cell detection
of 97% (808 cells in total) compared to the APAAP
method (838 cells in all 61 patients) was seen.
CK18-positive cell counts of the two methods were
positively correlated (Figure 5) with 
 
r
 
5
 
0.76 and 
 
p
 
,
 
0.001 (linear regression analysis).
Because variability of CK18-positive cell contents
among cytospins potentially detectable by immunocy-
tochemical methods should increase with a decrease in
overall CK18-positive cell numbers in 10
 
6
 
 and should
be highest in cases with very low CK18-positive cell
load, we additionally calculated the relative reproduc-
ibility of cell numbers for the 33 patients with 5 or
more CK18-positive cells in single APAAP separately.
Even in these cases with potentially more stable CK18-
positive cell distribution, the double staining protocol
revealed 94% (in total 735 compared to 783) of
CK18-positive cells detected in single APAAP staining.
 
Discussion
 
Our double staining method combines an immunoen-
zymatic step (streptavidin–biotin–APAAP) with an im-
munogold-method of high sensitivity. Danscher (1981)
and Holgate et al. (1983) first introduced immunogold
techniques that could be used for light microscopic
antigen detection by gold enhancement with silver pre-
cipitation. By further reducing the size of antibody-
conjugated gold particles to 1 nm, increasing the pene-
tration into cells (De Valck et al. 1991; Scopsi and
Larsson 1985), the use of gold-conjugated bridging
antibodies instead of direct marking of antigens (Scopsi
and Larsson 1985), and modification of precipitating
silver salts (Scopsi and Larsson 1985), the sensitivity
 
Table 1
 
Expression of uPA-R in cytospins of normal bone 
marrow
 
a
 
Diagnosis Positive cells per 1000 Percentage
Abdominal aortic aneurysm 64 6.4
Arterial occlusion 25 2.5
Rectal adenoma 145 14.5
Inguinal hernia 36 3.6
Leiomyoma 49 4.9
Inguinal hernia 112 11.2
Varicosis 79 7.9
Arterial occlusion 10 1.0
Hemolytic anemia 65 6.5
Healthy donor 61 6.1
Mean 
 
6
 
 SD 64.6 
 
6
 
 38.3 6.5 
 
6
 
 3.8
 
a
 
Expression of uPA-R in cytospin preparations of normal bone marrow. A to-
tal of 10
 
6
 
 cells were stained per patient and 1000 of them were counted rep-
resentatively for uPA-R staining.
 
Table 2
 
Comparison of sensitivity between the original and the modified staining protocol
 
a
 
Cell dilution Cells expected in 10
 
5
 
Cells detected with original protocol Cells detected in modified protocol
Mean SD % Mean SD %
1:10 10,000 8700 1077 87.0 9100 1221 91.0
1:100 1000 891 95 89.1 931 100 93.1
1:1000 100 91.8 7.0 91.8 93.7 6.9 93.7
1:10,000 10 7.9 1.2 79.0 9.6 1.6 96.0
1:100,000 1 0.7
 
b
 
0.6
 
b
 
70.0
 
b
 
0.9 0.7 90.0
1:200,000 0.5 0.1
 
b
 
0
 
b
 
20.0
 
b
 
0.3 0.5 60.0
1:300,000 0.3 0 0 0 0.2 0.4 66.7
1:500,000 0.2 0 0 0 0 0 0
1:1,000,000 0.1 0 0 0 0 0 0
 
a
 
Comparison of CK18-positive cell sensitivity between the staining protocol of Riesenberg et al. (1993) and our modification without glutaraldehyde postfixation
(see Materials and Methods). For this study, SW403 tumor cells were logarithmically diluted in PBL, and 10 slides with 10
 
5
 
 cells each stained with both protocols.
Means and standard deviations are given for the results of 10 slides stationed with each method.
 
b
 
Results of the original protocol (dilutions 1:100,000 and 1:200,000) indicate staining at very reduced intensity levels.
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of this method was optimized. This led to combina-
tion of the immunogold method with immunoenzy-
matic procedures for simultaneous marking of two an-
tigens (Sako et al. 1986; Scopsi and Larsson 1985;
Van den Pol 1984; Gu et al. 1981).
The advantage of this combination compared to
double enzymatic methods is avoidance of color mix-
ing, which often leads to false-negative results and in-
ability to clearly identify subcellular localizations of
the two antigens investigated (Riesenberg et al. 1993;
Mason and Woolston 1982). Especially in the case of
the CK18 antigen, low amounts of the second antigen,
which often occur in marking of membrane-bound re-
ceptors such as uPA-R, are often masked by strong
CK18 staining. This, however, is prevented by appli-
cation of immunogold for investigation of the second
antigen, which is reliably detected even at low amounts,
with good contrast to red CK18 staining and clear
identification of localization within the cell (Riesen-
berg et al. 1993).
Compared to immunofluorescence, our method en-
ables time-permanent preparations with visibility of
colors for years, and is more cost-effective (Antica et
al. 1986; Mason and Woolston 1982; Rathlev et al.
1981). Compared with immunoautoradiographic meth-
ods (Antica et al. 1986), it avoids exposure to harmful
radiation, and visualization of specific antigen mark-
ing takes about 1 hr compared to several days in im-
munoautoradiography (Antica et al. 1986).
An alternative to immunocytochemical double la-
beling could be provided by flow cytometry, which also
enables identification of more than one antigen even
quantitatively by multiplex labeling at sensitivities
reaching 1 cell in 1,000,000 (Shapiro 1995). How-
ever, for multiplex labeling in flow cytometry, the cell
types involved should be well characterized for un-
equivocal identification and differentiation, and inter-
mediate cell forms should not be present (Shapiro
1995). These intermediate cell forms, however, are a
major characteristic of bone marrow, a fact that could
limit applicability of this method to identification of
tumor cells in marrow samples. Furthermore, the use
of fixatives, often necessary to preserve cells for a few
days until screening is done, can lead to artifacts such
as autofluorescence (Shapiro 1995). Moreover, in con-
trast to flow cytometry, double immunocytochemistry
provides preparations that can be reinvestigated years
after staining. 
The sensitivity of our double staining protocol was
tested with logarithmic dilutions of tumor cells in com-
parison to Riesenberg’s original protocol. It was seen
that sensitivity (also considering easily visible staining
intensity) could be improved from 1:10,000 to
1:300,000 by omitting postfixation with glutaralde-
hyde, because higher CK2 antibody concentration (10
 
m
 
g/ml compared to 8 
 
m
 
g/ml in the original protocol)
alone had resulted in only poor improvement of sensi-
tivity (data not shown). The fixation mechanism of
glutaraldehyde is known to be alcylation of sulfhydryl
and COOH groups of cell membrane proteins, which
potentially decreases the permeability of cell mem-
branes to different molecules (Boenisch 1989). It is
conceivable that it also inhibits substrates of AP spe-
cifically bound to intracellular CK18 from permeat-
ing, thus lowering the intensity of the red staining re-
action. In addition, Guesdon et al. (1979) described
decreasing activity of avidin, which is part of the sec-
ond step in our double staining method, by applica-
tion of glutaraldehyde. This can explain the improve-
ment of sensitivity by omitting the glutaraldehyde step
of Riesenberg (Riesenberg et al. 1993). Background
staining as described by Guesdon et al. (1979) was not
enhanced in our modification, and subcellular antigen
localization could easily be identified despite the omis-
sion of postfixation.
Comparison of CK18-positive cell numbers detected
with our double staining method with APAAP–Fast
Blue results should allow estimation of reproducibil-
ity. In only four cases (CK18-positive cell numbers be-
tween 1 and 4; see Table 2) did our double staining
protocol fail to reproduce positive cells. Summarizing
Figure 5 Correlation diagram (scatter plot) showing the associa-
tion between CK18-positive cell counts in single APAAP and in our
double staining method. Each point in the graph represents one
patient, showing the number of positive cells detected with double
staining (x-axis) and with single APAAP (y-axis) for the individual
case. One patient with 280 cells in APAAP and 253 cells in double
staining is not shown in the graph. Correlation coefficient (r50.76)
and inclination of the regression line (y50.88X10.08) show posi-
tive association of APAAP and double staining results. Correlation
is significant, with p,0.001 (linear regression analysis).
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cell numbers of the 61 patients investigated, our dou-
ble staining protocol was able to detect 97% of CK18-
positive cells in APAAP. In 44% of cases, the double
staining method demonstrated even more cells than
the APAAP method. This can certainly be explained
by the variability of CK18-positive cell distribution
within the cytospin preparations, especially in patients
with low CK18-positive cell counts, as summarized
from investigation of 10 cytospins with 10
 
5 bone mar-
row cells each. Leaving out those cases with very low
CK18-positive cell counts in single APAAP (,5 in
106), we tried to decrease this influence, because with
higher CK18-positive cell numbers the variability of
detection due to incidental cell distribution between
cytospins should become more stable. Even here, the
double staining method detected 94% of the cell num-
ber in single APAAP, indicating good reproducibility.
Nevertheless, it should be emphasized that this com-
parison is an approximation for the true reproducibil-
ity of our method, because different cytospins with
potentially different CK18-positive cell numbers had
to be stained with single APAAP and the double stain-
ing protocol.
Because the immunogold step of our method is
known to be highly sensitive (De Valck et al. 1991;
Scopsi and Larsson 1985; Holgate et al. 1983), further
improvement of uPA-R marking by immunogold was
not the aim of our study. Nevertheless, further investi-
gations with different uPA-R antibodies compared to
MAb 3936 used here could lead to optimization of
uPA-R sensitivity, because specific binding of this an-
tibody may be lowered by high molecular weight uPA
or pro-uPA complexes (Chucholowski et al. 1992).
Preincubation with iodine or other oxidating sub-
stances (Holgate et al. 1983), thus enhancing the inter-
activeness of immunogold particles, may also lead to
optimization of the immunogold step.
uPA-R marking was present not only on CK18-pos-
itive cells but also on bone marrow cells. False-positivity
of this phenomenon was excluded by staining of normal
bone marrow for uPA-R with the established APAAP
method. Here, expression of uPA-R could be demon-
strated for a mean of 6.5% of cytospin bone marrow
cells. From the literature it is established that uPA-R is
expressed on blood leukocytes (e.g., monocytes, neu-
trophilic granulocytes, activated T-cells (Kramer et al.
1994; Blasi 1993), and bone marrow cytospins neces-
sarily contain a certain amount of sinusoidal blood.
This in itself provides an explanation for our findings.
In addition, Plesner et al. (1994) described that cyto-
kine stimulation of CD34-positive bone marrow stem
cells, which initially were uPA-R-negative, led to 40%
uPA-R-expressing bone marrow cells with advancing cell
differentiation in vitro. Discrepancy between Plesner’s
and our mean percentages of uPA-R-positive bone
marrow cells may, in our opinion, be explained by dif-
ferences between the physiological in vivo situation
and experimental in vitro stimulation.
Other authors, using the same double staining method,
also confirm the specific marking of the immunogold
step. Riesenberg et al. (1993) detected PSA exclusively
on disseminated prostate tumor cells and not in bone
marrow cells, which are known to be PSA-negative.
The proliferation antigen Ki67 is known to be ex-
pressed in bone marrow (Gerdes et al. 1984), and Pan-
tel et al. (1993b) described positive Ki67 staining of
CK18-positive as well as surrounding CK18-negative
bone marrow cells. In contrast, the same study did not
detect immunogold staining of bone marrow cells for
p120, a proliferation marker that is absent in bone
marrow (Pantel et al. 1993b).
The specificity of our method is further supported
by permanently negative isotype and cross-matched
controls. Background staining could be reduced to
minimum by extensive washing between the incuba-
tion steps, the importance of which is also confirmed
by Holgate et al. (1983) and by Scopsi and Larsson
(1985), who even postulate an increase of sensitivity
through prolonged washing when polyclonal antibod-
ies are used. Second, renewing the silver enhancement
solution after a maximal time of 20 min also led to re-
duced silver background.
In our present investigation, uPA-R was mainly de-
tected on cell membranes. In single cases of dissemi-
nated CK18-positive cells in bone marrow and also in
tumor cell line-positive controls, staining for uPA-R
was also localized on nuclear membranes. It is neces-
sary in further investigations to verify this nuclear
staining by electron microscopy. However, this find-
ing is corroborated by the report of Bastholm et al.
(1994), who describe paranuclear fluorescence pat-
terns investigating uPA-R in the breast cancer cell line
MDA-MB-231 by fluorescence microscopy. Jankun et
al. (1993), using the same MAb 3936 against uPA-R
as in our study, detected holonuclear staining in single
breast carcinomas investigated immunohistochemically
with the immunoperoxidase method. In this study, be-
nign breast tumors stained in comparison in 33% of
cases were uPA-R-negative, generally exhibited weaker
staining intensities than the carcinomas, and never
showed uPA-R localization in the nucleus. Therefore
uPA-R expression in the nucleus might be a character-
istic of malignancy, and further studies are desirable
to verify this hypothesis.
In summary, our present investigation suggests a
double staining protocol that allows highly sensitive
characterization of disseminated CK18-positive cells
in bone marrow, as well as good reproducibility, by
use of an established method. The first results regard-
ing correlation of uPA-R detection on those cells with
later increasing CK18-positive cell counts and a worse
prognosis for cancer patients (Heiss et al. 1995a,b) may
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lead to identification of aggressive phenotypes of sys-
temically spread tumor cells with this marker. There-
fore, the method may be helpful in evaluating the bio-
logical relevance of single individual cells to later
occurrence of clinical metastasis, which could be par-
ticularly important for patients with macroscopically
early tumor stages but evidence for subclinically spread
tumor cells. Our method might have broad applica-
tions in patients with various forms of epithelial can-
cer and in differentiating disseminated tumor cells by
patterns of other antigens. 
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